MISSOULA, MT, December 1, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel cancer immunotherapies and vaccine adjuvants and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a presentation at the upcoming MedInvest Oncology Conference in Palo Alto California December 5-6th. The event brings together oncology investors, researchers, and scientists from around the world to create new partnerships to bring the latest innovations in cancer therapy to clinical trials.
On Wednesday December 6th, Dr. Burkhart’s presentation titled “Harnessing the immune system to improve human health” at 9:40 am local time, will provide an introduction to Inimmune’s novel cancer immunotherapy INI-4001 which is set to begin a human clinical trial in January 2024. This presentation will highlight Inimmune’s extraordinary growth and use of advanced nanoparticle-based delivery systems to enhance INI-4001’s efficacy and safety, which are top priorities for the company. This meeting will bring together industry innovators in cancer detection, treatment, and investors interested in advancing human health in the fight against cancer.
Dr. Burkhart said, “The MedInvest Oncology conference is a great opportunity to present the impressive
preclinical data we’ve obtained with INI-4001 in multiple cancer solid tumor models, both alone and in
combination with existing check point therapies which synergize with INI-4001.” Current checkpoint therapies often do not benefit the majority of cancer patients. As INI-4001 is an innate immune system activator, it has the potential to greatly expand the percentage of patients who benefit from immunotherapy. An initial phase I human clinical trial will begin in Australia in January of 2024. Initially, INI-4001 will be used as a monotherapy to establish its safety profile and investigate the efficacy of INI-4001 alone. Subsequently, combinations of current checkpoint standard of care with INI-4001 will demonstrate whether patients benefit from combination therapy.
“Inimmune has made significant progress in the design and cGMP production of what we feel are best-
in-class adjuvants and adjuvant systems, and we look forward to seeing how these advancements impact future vaccines.” stated Dr. Kendal Ryter, VP Product Development at Inimmune.
“This is an exciting opportunity for Dr. Burkhart to share our latest oncology research with other leaders
in the immuno-oncology field,” said Alan Joslyn Ph.D., CEO of Inimmune. “Our participation in important
meetings such as this, highlights our ongoing commitment to developing novel vaccine adjuvants and demonstrates Inimmune’s position at the forefront of immunotherapeutic drug development.”
